These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

252 related items for PubMed ID: 20920042

  • 61. Mechanistic insights into the effects of quercetin and/or GLP-1 analogue liraglutide on high-fat diet/streptozotocin-induced type 2 diabetes in rats.
    Gaballah HH, Zakaria SS, Mwafy SE, Tahoon NM, Ebeid AM.
    Biomed Pharmacother; 2017 Aug; 92():331-339. PubMed ID: 28554128
    [Abstract] [Full Text] [Related]

  • 62. Long-term treatment with acylated analogues of apelin-13 amide ameliorates diabetes and improves lipid profile of high-fat fed mice.
    O'Harte FPM, Parthsarathy V, Hogg C, Flatt PR.
    PLoS One; 2018 Aug; 13(8):e0202350. PubMed ID: 30157220
    [Abstract] [Full Text] [Related]

  • 63. XMetA, an allosteric monoclonal antibody to the insulin receptor, improves glycaemic control in mice with diet-induced obesity.
    Bhaskar V, Lau A, Goldfine ID, Narasimha AJ, Gross LM, Wong S, Cheung B, White ML, Corbin JA.
    Diabetes Obes Metab; 2013 Mar; 15(3):272-5. PubMed ID: 23039274
    [Abstract] [Full Text] [Related]

  • 64. Liraglutide suppresses obesity and hyperglycemia associated with increases in hepatic fibroblast growth factor 21 production in KKAy mice.
    Nonogaki K, Hazama M, Satoh N.
    Biomed Res Int; 2014 Mar; 2014():751930. PubMed ID: 24804243
    [Abstract] [Full Text] [Related]

  • 65. Synergistic effect of the human GLP-1 analogue liraglutide and a dual PPARalpha/gamma agonist on glycaemic control in Zucker diabetic fatty rats.
    Brand CL, Galsgaard ED, Tornehave D, Rømer J, Gotfredsen CF, Wassermann K, Knudsen LB, Vølund A, Sturis J.
    Diabetes Obes Metab; 2009 Aug; 11(8):795-803. PubMed ID: 19519868
    [Abstract] [Full Text] [Related]

  • 66. Attempted suicide with liraglutide overdose did not induce hypoglycemia.
    Nakanishi R, Hirose T, Tamura Y, Fujitani Y, Watada H.
    Diabetes Res Clin Pract; 2013 Jan; 99(1):e3-4. PubMed ID: 23149376
    [Abstract] [Full Text] [Related]

  • 67. Optimization of tolerability and efficacy of the novel dual amylin and calcitonin receptor agonist KBP-089 through dose escalation and combination with a GLP-1 analog.
    Gydesen S, Andreassen KV, Hjuler ST, Hellgren LI, Karsdal MA, Henriksen K.
    Am J Physiol Endocrinol Metab; 2017 Nov 01; 313(5):E598-E607. PubMed ID: 28292761
    [Abstract] [Full Text] [Related]

  • 68. Liraglutide for Type 2 diabetes and obesity: a 2015 update.
    Iepsen EW, Torekov SS, Holst JJ.
    Expert Rev Cardiovasc Ther; 2015 Nov 01; 13(7):753-67. PubMed ID: 26106933
    [Abstract] [Full Text] [Related]

  • 69. The type 2 diabetes drug liraglutide reduces chronic inflammation induced by irradiation in the mouse brain.
    Parthsarathy V, Hölscher C.
    Eur J Pharmacol; 2013 Jan 30; 700(1-3):42-50. PubMed ID: 23276669
    [Abstract] [Full Text] [Related]

  • 70. Reduction in TNF alpha and oxidative stress by liraglutide: Impact on ketamine-induced cognitive dysfunction and hyperlocomotion in rats.
    Sedky AA, Magdy Y.
    Life Sci; 2021 Aug 01; 278():119523. PubMed ID: 33891942
    [Abstract] [Full Text] [Related]

  • 71.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 72. Chronic administration of the glucagon-like peptide-1 analog, liraglutide, delays the onset of diabetes and lowers triglycerides in UCD-T2DM rats.
    Cummings BP, Stanhope KL, Graham JL, Baskin DG, Griffen SC, Nilsson C, Sams A, Knudsen LB, Raun K, Havel PJ.
    Diabetes; 2010 Oct 01; 59(10):2653-61. PubMed ID: 20622169
    [Abstract] [Full Text] [Related]

  • 73. Glp-1 analog, liraglutide, ameliorates hepatic steatosis and cardiac hypertrophy in C57BL/6J mice fed a Western diet.
    Mells JE, Fu PP, Sharma S, Olson D, Cheng L, Handy JA, Saxena NK, Sorescu D, Anania FA.
    Am J Physiol Gastrointest Liver Physiol; 2012 Jan 15; 302(2):G225-35. PubMed ID: 22038829
    [Abstract] [Full Text] [Related]

  • 74. A novel oral form of salmon calcitonin improves glucose homeostasis and reduces body weight in diet-induced obese rats.
    Feigh M, Henriksen K, Andreassen KV, Hansen C, Henriksen JE, Beck-Nielsen H, Christiansen C, Karsdal MA.
    Diabetes Obes Metab; 2011 Oct 15; 13(10):911-20. PubMed ID: 21615667
    [Abstract] [Full Text] [Related]

  • 75. Deterioration of plasticity and metabolic homeostasis in the brain of the UCD-T2DM rat model of naturally occurring type-2 diabetes.
    Agrawal R, Zhuang Y, Cummings BP, Stanhope KL, Graham JL, Havel PJ, Gomez-Pinilla F.
    Biochim Biophys Acta; 2014 Sep 15; 1842(9):1313-23. PubMed ID: 24840661
    [Abstract] [Full Text] [Related]

  • 76.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 77. The effects of liraglutide in mice with diet-induced obesity studied by metabolomics.
    Bugáňová M, Pelantová H, Holubová M, Šedivá B, Maletínská L, Železná B, Kuneš J, Kačer P, Kuzma M, Haluzík M.
    J Endocrinol; 2017 Apr 15; 233(1):93-104. PubMed ID: 28138003
    [Abstract] [Full Text] [Related]

  • 78. Beneficial effects of once-daily liraglutide, a human glucagon-like peptide-1 analogue, on cardiovascular risk biomarkers in patients with Type 2 diabetes.
    Courrèges JP, Vilsbøll T, Zdravkovic M, Le-Thi T, Krarup T, Schmitz O, Verhoeven R, Bugáñová I, Madsbad S.
    Diabet Med; 2008 Sep 15; 25(9):1129-31. PubMed ID: 19183322
    [No Abstract] [Full Text] [Related]

  • 79. Prophylactic effects of the glucagon-like Peptide-1 analog liraglutide on hyperglycemia in a rat model of type 2 diabetes mellitus associated with chronic pancreatitis and obesity.
    Nagakubo D, Shirai M, Nakamura Y, Kaji N, Arisato C, Watanabe S, Takasugi A, Asai F.
    Comp Med; 2014 Apr 15; 64(2):121-7. PubMed ID: 24674587
    [Abstract] [Full Text] [Related]

  • 80. Liraglutide prevents metabolic side-effects and improves recognition and working memory during antipsychotic treatment in rats.
    Babic I, Gorak A, Engel M, Sellers D, Else P, Osborne AL, Pai N, Huang XF, Nealon J, Weston-Green K.
    J Psychopharmacol; 2018 May 15; 32(5):578-590. PubMed ID: 29493378
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 13.